Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733488 | 0.92 | TP53 (0.33) | TP53TSPOLMNAALDH1A1TSHR | |
| SCHEMBL21733838 | 0.89 | TP53 (0.32) | TP53TSPOALDH1A1TSHRUSP2 | |
| SCHEMBL26268266 | 0.89 | TP53 (0.32) | TP53TSPOALDH1A1TSHRUSP2 | |
| SCHEMBL26268592 | 0.84 | ALDH1A1 (0.34) | TP53LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL21733627 | 0.82 | TP53 (0.33) | TP53LMNAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL26269144 | 0.80 | TP53 (0.31) | TP53TSPOALDH1A1TSHRUSP2 | |
| SCHEMBL28493072 | 0.80 | TSPO (0.32) | TSPOALDH1A1TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL21733489 | 0.80 | TSPO (0.31) | TSPOALDH1A1TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL21733858 | 0.75 | PDE10A (0.33) | TP53LMNAALDH1A1TSHRUSP2 | |
| SCHEMBL21733814 | 0.75 | ACHE (0.32) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119075-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-112119075-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-22 | — | — | CN | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | TP53 23/4885TSPO 2970/4885LMNA 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.